HKEX: 9606
Next Day Disclosure Return
Earlier from Duality Biotherapeutics
- 2026 Interim report
- DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
- DualityBio (9606.HK) Announces 2025 Annual Results
- DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation